Romvimza
Payments companies reported to CMS as associated with Romvimza. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Romvimza, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Romvimza
These are the largest totals companies reported as associated with Romvimza. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Thomas Scharschmidt | Columbus, OH | Orthopaedic Surgery | $24,811.19 |
| Atrayee Basu Mallick | Philadelphia, PA | Hematology & Oncology | $12,903.36 |
| Arun Singh | Santa Monica, CA | Hematology & Oncology | $12,033.31 |
| Seth Pollack | Chicago, IL | Hematology & Oncology | $9,181.56 |
| Vicki Keedy | Nashville, TN | Medical Oncology | $8,047.50 |
| Brian Rubin | Cleveland, OH | Anatomic Pathology | $5,600.00 |
| Solange Sierra | Miami, FL | Nurse Practitioner | $5,014.40 |
| Mark Agulnik | Los Angeles, CA | Medical Oncology | $3,694.55 |
| Steven Thorpe | Aurora, CO | Orthopaedic Surgery | $3,148.43 |
| Breelyn Wilky | Aurora, CO | Hematology & Oncology | $3,136.79 |
Prescribed Romvimza?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.